{"title":"美国临床肿瘤学会","authors":"","doi":"10.32388/wgy03s","DOIUrl":null,"url":null,"abstract":"distinct and molecular subtypes lymphoma (DLBCL): (GCB) lymphoma, clinical and clinical trials identifying who in a high-risk Stomatitis occurs in approximately 65% of patients who are being treated with everolimus. Dr. Rugo’s meta-analysis of seven clinical trials looked at a total of 1,455 patients, 973 of whom developed stomatitis—89% within eight weeks of initiat-ing therapy. Forty percent of patients had a second onset of stomatitis. The dose of everolimus used in each of the seven trials was 10 mg/day. Bevacizumab targets vascular endothelial growth factor (VEGF)-blocking angiogenesis, and cetuximab blocks epider-mal growth factor receptor (EGFR), a protein affecting cancer growth and spread. Leukemia Oncology showed that for wild-type KRAS gene-mutated metastatic colorectal cancer patients, first-line treatment with and either of two targeted drugs, bevacizumab or cetuximab, led to similar median survival of about 29 months. re-analysis of a clinical trial taking into account the effect of large numbers of multiple myeloma patients switching to the more active treatment regimen the benefit shown in the original analysis.","PeriodicalId":38773,"journal":{"name":"P and T","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"407","resultStr":"{\"title\":\"American Society of Clinical Oncology\",\"authors\":\"\",\"doi\":\"10.32388/wgy03s\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"distinct and molecular subtypes lymphoma (DLBCL): (GCB) lymphoma, clinical and clinical trials identifying who in a high-risk Stomatitis occurs in approximately 65% of patients who are being treated with everolimus. Dr. Rugo’s meta-analysis of seven clinical trials looked at a total of 1,455 patients, 973 of whom developed stomatitis—89% within eight weeks of initiat-ing therapy. Forty percent of patients had a second onset of stomatitis. The dose of everolimus used in each of the seven trials was 10 mg/day. Bevacizumab targets vascular endothelial growth factor (VEGF)-blocking angiogenesis, and cetuximab blocks epider-mal growth factor receptor (EGFR), a protein affecting cancer growth and spread. Leukemia Oncology showed that for wild-type KRAS gene-mutated metastatic colorectal cancer patients, first-line treatment with and either of two targeted drugs, bevacizumab or cetuximab, led to similar median survival of about 29 months. re-analysis of a clinical trial taking into account the effect of large numbers of multiple myeloma patients switching to the more active treatment regimen the benefit shown in the original analysis.\",\"PeriodicalId\":38773,\"journal\":{\"name\":\"P and T\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"407\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"P and T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32388/wgy03s\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"P and T","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32388/wgy03s","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
distinct and molecular subtypes lymphoma (DLBCL): (GCB) lymphoma, clinical and clinical trials identifying who in a high-risk Stomatitis occurs in approximately 65% of patients who are being treated with everolimus. Dr. Rugo’s meta-analysis of seven clinical trials looked at a total of 1,455 patients, 973 of whom developed stomatitis—89% within eight weeks of initiat-ing therapy. Forty percent of patients had a second onset of stomatitis. The dose of everolimus used in each of the seven trials was 10 mg/day. Bevacizumab targets vascular endothelial growth factor (VEGF)-blocking angiogenesis, and cetuximab blocks epider-mal growth factor receptor (EGFR), a protein affecting cancer growth and spread. Leukemia Oncology showed that for wild-type KRAS gene-mutated metastatic colorectal cancer patients, first-line treatment with and either of two targeted drugs, bevacizumab or cetuximab, led to similar median survival of about 29 months. re-analysis of a clinical trial taking into account the effect of large numbers of multiple myeloma patients switching to the more active treatment regimen the benefit shown in the original analysis.